News

Patient-controlled epidural analgesia similar to intravenous


 

FROM BMC MUSCULOSKELETAL DISORDERS

References

Patient-controlled epidural analgesia achieves pain control similar to that of patient-controlled intravenous analgesia after spinal fusion surgery, but is associated with a higher incidence of pruritus and paresthesia, a meta-analysis published in BMC Musculoskeletal Disorders has found.

The analysis of eight randomized controlled trials involving 482 patients found that patient-controlled epidural analgesia was associated with significantly better analgesic effects on day 1 and 2 after surgery (mean difference in visual analog scale scores of −0.47 and −0.66, respectively), but this difference was no longer statistically significant on day 3.

Thomas Northcut/ ©Thinkstock

The study, conducted by Dr. Peng Tian of Tianjin (China) Hospital and colleagues showed that patient-controlled epidural analgesia was associated with a significant 53% higher incidence of pruritus and a threefold increase in paresthesia, compared with patient-controlled intravenous analgesia, although there were no significant differences in the rates of nausea or vomiting (BMC Musculoskeletal Disorders 2015 Dec 15. doi: 10.1186/s12891-015-0849-y).

Researchers noted that patient-controlled epidural analgesia achieves a faster analgesic effect than does patient-controlled intravenous analgesia because it acts directly on the near-operative region, but the analgesic effect of the intravenous administration lasts longer.

“The most important findings of the present meta-analysis are that the application of PCEA [patient-controlled epidural analgesia] does not more effectively relieve” pain in 3 postoperative days compared with patient-controlled intravenous analgesia, “meanwhile increasing the incidence of some complications such as pruritus and paresthesia,” wrote the investigators.

The National Natural Science Foundation of China supported the study. No conflicts of interest were declared.

Recommended Reading

FDA rejects antisense oligonucleotide drug for Duchenne muscular dystrophy
MDedge Neurology
VIDEO: Expert discusses VATS thymectomy for myasthenia gravis
MDedge Neurology
USPSTF: Screen all adults for depression
MDedge Neurology
New test showed promise in ocular myasthenia gravis
MDedge Neurology
Lysolipid antigens prominent in MGUS and myeloma
MDedge Neurology
Human gene editing consensus study underway
MDedge Neurology
Stronger evidence links Zika to Guillain-Barré syndrome
MDedge Neurology
New CDC opioid guideline targets overprescribing for chronic pain
MDedge Neurology
ABMS approves new addiction medicine subspecialty
MDedge Neurology
Addiction – how are we being played?
MDedge Neurology